New Mesothelioma Immunotherapy Trial Now Underway at Baylor

mesothelioma immunotherapy trial

Cancer researchers at Baylor College of Medicine have launched a new mesothelioma immunotherapy trial. The trial combines the cancer drug Opdivo (nivolumab) with injections of a modified virus called MTG201. Baylor scientists are hoping to recruit 12 pleural mesothelioma patients whose cancer has come back after chemotherapy.  The treatment combination appeared to work well in mice with mesothelioma. If it works as well in people, this new mesothelioma immunotherapy trial could change the outlook for many people with malignant mesothelioma.  How the New Mesothelioma Immunotherapy Trial Will Work Opdivo is the brand name for nivolumab. It blocks a protein called PD-1 in cancer cells. PD-1 is one of the ways that mesothelioma cells evade the immune system. Opdivo is often … Continue reading New Mesothelioma Immunotherapy Trial Now Underway at Baylor »

Cediranib for Mesothelioma: VEGF Inhibitor Fails Another Trial

cediranib for mesothelioma

Cediranib for mesothelioma appears to be ruled out by another failed clinical trial.  A new study led by MD Anderson researchers concludes that the VEGF inhibitor causes too many side effects for not enough survival benefit.  It is a blow to researchers hoping to use cediranib for mesothelioma patients on chemotherapy.  Cutting Off Tumor Blood Supply Cediranib is an oral drug made by AstraZeneca. It is part of a class of drugs called VEGF inhibitors. Vascular endothelial growth factor (VEGF) is a signal protein that stimulates blood vessel formation in tumors. Research shows that mesothelioma patients who have higher serum levels of VEGF have a lower chance of survival.  VEGF inhibitors like cediranib latch onto VEGF receptors inside mesothelioma cells. … Continue reading Cediranib for Mesothelioma: VEGF Inhibitor Fails Another Trial »

Experimental Mesothelioma Treatment Targets Tumor Growth Compounds

Experimental mesothelioma treatment

Hong Kong researchers have released the first results of an experimental mesothelioma treatment they are working on. The treatment targets organic compounds believed to contribute to mesothelioma growth. The trial took place at the University of Hong Kong. Mice with mesothelioma received doses of an enzyme inhibitor called DFMO. The drug appears to stop the production of organic compounds called polyamines. In tests, mice with lower polyamine levels lived longer with pleural mesothelioma. Enzymes Contribute to Tumor Growth The growth and spread of pleural mesothelioma is a complex process. It involves many different proteins and enzymes working together. Scientists have not yet identified all of the compounds that contribute to cancer growth. But the experimental mesothelioma treatment in Hong Kong … Continue reading Experimental Mesothelioma Treatment Targets Tumor Growth Compounds »

Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin

advanced peritoneal mesothelioma

European doctors have tested a new spray-on cancer drug that could be another treatment option for people with advanced peritoneal mesothelioma. The drug is oxaliplatin. It is sold under the brand name Eloxatin. It is normally given by injection into a vein. But that can cause serious side effects, including stomach pain. A new study published in the European Journal of Surgical Oncology suggests there may be a more effective way to get the benefits of oxaliplatin. Researchers found that using it as a spray for advanced peritoneal mesothelioma extended survival with fewer side effects. PIPAC for Advanced Peritoneal Mesothelioma As Surviving Mesothelioma first reported last spring, pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new way to deliver cancer medicines. … Continue reading Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin »

Ofev Shelved as a Treatment for Pleural Mesothelioma

Treatment for pleural mesothelioma

It is official – the VEGF inhibitor Ofev is out of the running as a treatment for pleural mesothelioma. Hopes had been high for this drug after initial results showed a survival advantage. For the last two years, Ofev (nintedanib) was the subject of a large, international clinical trial. But now the leaders of that trial have published their Phase III trial results in The Lancet: Respiratory Medicine. They show that Ofev did not extend survival and is not an effective treatment for pleural mesothelioma. Why Hopes Were High for Ofev Ofev is an oral medication that stops cancer cells from producing a protein called VEGF. VEGF promotes the growth of blood vessels that help mesothelioma tumors grow. VEGF may … Continue reading Ofev Shelved as a Treatment for Pleural Mesothelioma »

Combination Mesothelioma Therapy Begins Pivotal Trial

mesothelioma treatment combination

A combination mesothelioma therapy that showed promise in early trials is finally being studied on a larger scale. The power-packed chemo-immuno-gene therapy known as TR002 has the potential to change the outlook for thousands of malignant mesothelioma patients. A small trial of the combination mesothelioma therapy in 2016 produced “significantly higher” mesothelioma survival rates than most patients are told to expect. Drug company Trizell announced last month that the combination will now be tested on 300 patients at sites in the US, Europe, Australia and Russia. Combination Mesothelioma Therapy Starts with Gene Therapy TR002 is an investigational gene therapy for mesothelioma patients who have failed first-line chemotherapy. This combination mesothelioma therapy is based on the human interferon-alpha 2b gene. The … Continue reading Combination Mesothelioma Therapy Begins Pivotal Trial »

New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy

mesothelioma clinical trial of dendritic cells

A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy »

PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma

mesothelioma immunotherapy response

A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have … Continue reading PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma »

Defactinib Fails Again as a Maintenance Therapy for Mesothelioma

patient chemotherapy for mesothelioma

There has been another setback for a drug that showed promise as a maintenance therapy for mesothelioma. Defactinib is a focal adhesion kinase (FAK) inhibitor. FAK is a signaling pathway that allows stem cells to give rise to new cancer cells. The developers of defactinib hoped that FAK inhibition would help keep mesothelioma tumors from growing back after chemotherapy. But a team of international researchers has once again concluded that the drug does not work as a maintenance therapy for mesothelioma. In Search of a Maintenance Therapy for Mesothelioma Malignant pleural mesothelioma is an aggressive cancer that is very hard to treat. Standard chemotherapy drugs like pemetrexed, cisplatin, gemcitabine and vinorelbine can sometimes shrink tumors, but they usually come back. Doctors … Continue reading Defactinib Fails Again as a Maintenance Therapy for Mesothelioma »

New Mesothelioma Drug Trial Begins

mesothelioma drug trial

A new mesothelioma drug trial is now underway. The trial will test a brand new type of immunotherapy medication called CA-170. CA-170 is designed to block an immune system suppressor called VISTA. It is the only VISTA-blocking medication currently in clinical trial. “CA-170 has demonstrated favorable safety and tolerability as well as preliminary anti-tumor activity in patients across multiple tumor types,” the company said in a statement. Mesothelioma Drug Trial Focuses on VISTA Malignant mesothelioma is highly resistant to standard cancer treatments. Many top researchers believe that immunotherapy drugs offer the best promise for curing mesothelioma. That is because cancers like malignant mesothelioma survive in part by evading detection by the immune system. They do this in a variety ways … Continue reading New Mesothelioma Drug Trial Begins »

Get your free copy of
“Surviving Mesothelioma” Today!